212 related articles for article (PubMed ID: 22833806)
1. Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease.
Bennett CL; Qureshi ZP; Sartor AO; Norris LB; Murday A; Xirasagar S; Thomsen HS
Clin Kidney J; 2012 Feb; 5(1):82-88. PubMed ID: 22833806
[TBL] [Abstract][Full Text] [Related]
2. Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.
Schieda N; Blaichman JI; Costa AF; Glikstein R; Hurrell C; James M; Jabehdar Maralani P; Shabana W; Tang A; Tsampalieros A; van der Pol CB; Hiremath S
Can J Kidney Health Dis; 2018; 5():2054358118778573. PubMed ID: 29977584
[TBL] [Abstract][Full Text] [Related]
3. Gadolinium-Based Contrast Agents in Kidney Disease: Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.
Schieda N; Blaichman JI; Costa AF; Glikstein R; Hurrell C; James M; Jabehdar Maralani P; Shabana W; Tang A; Tsampalieros A; van der Pol C; Hiremath S
Can Assoc Radiol J; 2018 May; 69(2):136-150. PubMed ID: 29706252
[TBL] [Abstract][Full Text] [Related]
4. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
[TBL] [Abstract][Full Text] [Related]
5. Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. a report from the Southern Network on Adverse Reactions (SONAR).
Bennett CL; Starko KM; Thomsen HS; Cowper S; Sartor O; Macdougall IC; Qureshi ZP; Bookstaver PB; Miller AD; Norris LB; Xirasagar S; Trenery A; Lopez I; Kahn A; Murday A; Luminari S; Cournoyer D; Locatelli F; Ray P; Mattison DR
J Gen Intern Med; 2012 Dec; 27(12):1697-703. PubMed ID: 22692632
[TBL] [Abstract][Full Text] [Related]
6. Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark.
Elmholdt TR; Pedersen M; Jørgensen B; Søndergaard K; Jensen JD; Ramsing M; Olesen AB
Br J Dermatol; 2011 Oct; 165(4):828-36. PubMed ID: 21692765
[TBL] [Abstract][Full Text] [Related]
7. Updated Clinical Practice Guideline on Use of Gadolinium-Based Contrast Agents in Kidney Disease Issued by the Canadian Association of Radiologists.
Schieda N; Maralani PJ; Hurrell C; Tsampalieros AK; Hiremath S
Can Assoc Radiol J; 2019 Aug; 70(3):226-232. PubMed ID: 31255393
[TBL] [Abstract][Full Text] [Related]
8. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent.
Rydahl C; Thomsen HS; Marckmann P
Invest Radiol; 2008 Feb; 43(2):141-4. PubMed ID: 18197066
[TBL] [Abstract][Full Text] [Related]
9. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned.
Broome DR; Girguis MS; Baron PW; Cottrell AC; Kjellin I; Kirk GA
AJR Am J Roentgenol; 2007 Feb; 188(2):586-92. PubMed ID: 17242272
[TBL] [Abstract][Full Text] [Related]
10. Nephrogenic systemic fibrosis: center case review.
Lauenstein TC; Salman K; Morreira R; Tata S; Tudorascu D; Baramidze G; Singh-Parker S; Martin DR
J Magn Reson Imaging; 2007 Nov; 26(5):1198-203. PubMed ID: 17969162
[TBL] [Abstract][Full Text] [Related]
11. Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol.
Elmholdt TR; Jørgensen B; Ramsing M; Pedersen M; Olesen AB
NDT Plus; 2010 Jun; 3(3):285-287. PubMed ID: 28657062
[TBL] [Abstract][Full Text] [Related]
12. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.
Woolen SA; Shankar PR; Gagnier JJ; MacEachern MP; Singer L; Davenport MS
JAMA Intern Med; 2020 Feb; 180(2):223-230. PubMed ID: 31816007
[TBL] [Abstract][Full Text] [Related]
13. Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases.
Tsushima Y; Kanal E; Thomsen HS
Br J Radiol; 2010 Jul; 83(991):590-5. PubMed ID: 20413447
[TBL] [Abstract][Full Text] [Related]
14. Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review.
Rudnick MR; Wahba IM; Leonberg-Yoo AK; Miskulin D; Litt HI
Am J Kidney Dis; 2021 Apr; 77(4):517-528. PubMed ID: 32861792
[TBL] [Abstract][Full Text] [Related]
15. An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital.
Marckmann P
Eur J Radiol; 2008 May; 66(2):187-90. PubMed ID: 18328659
[TBL] [Abstract][Full Text] [Related]
16. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.
Altun E; Martin DR; Wertman R; Lugo-Somolinos A; Fuller ER; Semelka RC
Radiology; 2009 Dec; 253(3):689-96. PubMed ID: 19789233
[TBL] [Abstract][Full Text] [Related]
17. [Nephrogenic systemic fibrosis].
Breitschaft A; Stahlmann R
Med Monatsschr Pharm; 2009 Oct; 32(10):377-82. PubMed ID: 19886227
[TBL] [Abstract][Full Text] [Related]
18. Nephrogenic systemic fibrosis: review of 408 biopsy-confirmed cases.
Zou Z; Ma L
Indian J Dermatol; 2011 Jan; 56(1):65-73. PubMed ID: 21572796
[TBL] [Abstract][Full Text] [Related]
19. Incidence of nephrogenic systemic fibrosis at two large medical centers.
Prince MR; Zhang H; Morris M; MacGregor JL; Grossman ME; Silberzweig J; DeLapaz RL; Lee HJ; Magro CM; Valeri AM
Radiology; 2008 Sep; 248(3):807-16. PubMed ID: 18710976
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
